Immune Checkpoint Inhibitors Market Future Scope (2023-2028): Key Factors, Status and Forecast
The Immune Checkpoint Inhibitors Market is likely to grow at a rate of 13.1% CAGR by 2028.
Market Research Engine has published a new report titled as “Immune Checkpoint Inhibitors Market based on Type (CTLA-4 Inhibitor, PD-1 Inhibitor and PD-L1 Inhibitor), Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma and Others) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2023 -2028.”
Browse Full Report: https://www.marketresearchengine.com/herpes-simplex-virus-treatment-market
Immune checkpoints are a usual part of the immune system. Their duty is to avoid an immune response from being so strong which it destroys healthy cells in the body. Immune checkpoints capture when proteins on the surface of immune cells known as T cells recognize and hold to partner proteins in other cells, such as few tumor cells. These proteins are known as immune checkpoint proteins. Rise & innovations in the pharmaceutical industry for cancer treatment has become more refined with enhanced treatment success rate owing to the better therapeutic outcomes. This has been possible owing to a better understanding of the disease pathophysiology, the functioning of the tumor cells, and effective ways to address the increasing cancer rate creates an opportunity for the immune checkpoint inhibitors market growth. On the other hand, the high expenses incurred in the immuno-oncology therapies which are unaffordable for middle and low class people may hinder the market growth. The Immune Checkpoint Inhibitors Market is likely to grow at a rate of 13.1% CAGR by 2028.
The Immune Checkpoint Inhibitors Market has been segmented as below:
Immune Checkpoint Inhibitors Market based on Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
Immune Checkpoint Inhibitors Market based on Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Colorectal Cancer
- Hodgkin lymphoma
- Others
Immune Checkpoint Inhibitors Market based on Geography
- North America
- Europe
- Asia Pacific
- Rest of the World
On the basis of type, the Immune Checkpoint Inhibitors market is divided into CTLA-4 Inhibitor, PD-1 Inhibitor and PD-L1 Inhibitor. The PD-1 inhibitors segment is likely to have a significant share in the market. PD-1 inhibitors are a group of immune checkpoint inhibitors used as first-line therapy for a variety of cancers. Despite the potential therapeutic outcomes, the considerable immune-related side effects restricted the clinical deployment of PD-1 monoclonal antibodies. The dominance of the segment can be ascribed to the high volume of research activities, approvals, and the increase in prescriptions of these drugs such as nivolumab and pembrolizumab.
In the market based on application, the Immune Checkpoint Inhibitors market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma and Others. The lung cancer segment holds the highest share in the market and anticipated to grow in the future period. It is the result of a rise in pharmacological approvals for the treatment of several solid tumors in the past four years. The market has also seen high research for the treatment of urogenital cancer, as well as several approvals for various technical improvements in the treatment of several tumors, which has contributed to the segment’s growth.
As per the geographical analysis of the market, the North America region has occupied a considerable share in the Immune Checkpoint Inhibitors market. One of the major factors for the swift growth of the North America Immune Checkpoint Inhibitors Market is the sale of authorized therapies and the increasing occurrence of blood-related cancers. In addition, the increasing number of patient support programs provided by vendors is accelerating the market in this area forward.
Furthermore, the adoption of an unhealthy lifestyle, surging cases of cancer, and genetic modification and alteration affects the global healthcare cost, thus it helps to boost the growth of the immune checkpoint inhibitor market. Additionally, the technological advancement in the screening or broadcast method for cancer and rising healthcare expenditures in this market, the rise in the adoption of immune checkpoint inhibitor drugs in developing markets, are factors fueling the growth of the global immune checkpoint inhibitors market.
Key players operating in the market include AstraZeneca PLC, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Shanghai Jhunsi Biosciences Ltd, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline Plc, Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd.
As a result, the immune checkpoint inhibitors play a significant role in the treatment of dreadful diseases such as lung cancer and melanoma skin cancer. Immune checkpoint inhibitors are widely being used in the treatment for cancers as a type immunotherapy.
- This report elucidates how the various attributes are impacting the Immune Checkpoint Inhibitors market growth in the forecasted time span.
- This research provides thorough analysis of the segments and sub segments of the market and their key contributions in the market growth.
- This report comprises of the exclusive depiction of the competitive outlook coupled with key strategies deployed by the market competitors.
- This research further covers quantitative analysis of the market in terms of geography which gives a perception of the regional market.
Request Sample Report from here: https://www.marketresearchengine.com/immune-checkpoint-inhibitors-market
TABLE OF CONTENTS
- Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
5. Type: Market Size & Analysis6. Application: Market Size & Analysis
7. Geography: Market Size & Analysis
8. Competitive Landscape
9. Vendor Profiles
9.1. AstraZeneca PLC
9.2. F. Hoffmann-La Roche Ltd (Genentech, Inc.,)
9.3. Shanghai Jhunsi Biosciences Ltd
9.4. Bristol-Myers Squibb Company
9.5. Eli Lilly and Company (ARMO Biosciences.)
9.6. GlaxoSmithKline Plc
9.7. Sanofi
9.8. Merck & Co., Inc.
9.9. Merck KGaA (EMD Serono, Inc.)
9.10. BeiGene Ltd
10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
About MarketResearchEngine.com
Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.
Other Related Market Research Reports:
Athleisure Market Industry Analysis and Detailed Profiles of top Industry Players the COVID-19
Herpes Simplex Virus Treatment Market Future Scope (2024-2027): Key Factors, Status and Forecast
Activated Bleaching Earth Market Size predicts favorable growth and forecast 2020 – 2026
Media Contact
Company Name: Market Research Engine
Contact Person: John Bay
Email: [email protected]
Phone: +1-855-984-1862
Country: United States
